Skip to main content


Log in

Intra-arterial Carboplatin and Intravenous Etoposide for the Treatment of Recurrent and Progressive Non-GBM Gliomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript


Recurrent and progressive non-GBM gliomas are a diverse group of brain tumors that often respond poorly to adjuvant chemotherapy treatment. Regional intra-arterial (IA) administration of chemotherapy may result in increased tumor uptake of drug, with improvement in response rates and time to progression (TTP). Twenty-five patients with recurrent or progressive non-GBM gliomas were treated with IA carboplatin (200 mg/m2/d) and intravenous (IV) etoposide (100 mg/m2/d) for 2 days every 4 weeks. Patients ranged in age from 22 to 68 years (mean 37.8). All but one patient had received standard irradiation, and eight patients had attempted prior chemotherapy. Five of 25 patients had objective responses (20%), while another 15 patients had stable disease (60%), receiving a total of 318 IA treatment procedures. There was one complete response (4.0%), three partial responses (12.0%), one minor response (4.0%), 15 stable diseases (60.0%), and five progressive diseases (20.0%). The median TTP was 24.2 weeks overall and 32 weeks in responders. Overall median survival was 34.2 weeks. Therapy was well tolerated, with mainly hematologic toxicity. Two patients had embolic complications. Although these are preliminary results, IA carboplatin and IV etoposide have modest activity against recurrent and progressive non-GBM gliomas and warrants further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Newton HB: Primary brain tumors: review of etiology, diagnosis, and treatment. Am Fam Phys 49: 787-797, 1994

    Google Scholar 

  2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WKA: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999

    Google Scholar 

  3. Kyritsis AP, Yung WKA, Bruner J, Gleason MJ, Levin VA: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32: 365-371, 1993

    Google Scholar 

  4. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG: Salvage chemotherapy for oligodendrgoglioma. J Neurosurg 85: 597-601, 1996

    Google Scholar 

  5. Newton HB, Turowski RC, Stroup TJ, McCoy LK: Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 33: 816-832, 1999

    Google Scholar 

  6. Yung WKA, Mechteler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9: 860-864, 1991

    Google Scholar 

  7. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 10: 1074-1077, 1992

    Google Scholar 

  8. Stewart DJ: Pros and cons of intra-arterial chemotherapy. Oncology 3: 20-26, 1989

    Google Scholar 

  9. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, Mealey J, Ransohoff J, Mahaley MS: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76: 772-781, 1992

    Google Scholar 

  10. Newton HB, Page MA, Junck L, Greenberg HS: Intraarterial cisplatin for the treatment of malignant gliomas. J Neuro-Oncol 7: 39-45, 1989

    Google Scholar 

  11. Dropcho EJ, Rosenfeld SS, Vitek J, Guthrie BL, Morawetz RB: Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neuro-Oncol 36: 191-198, 1998

    Google Scholar 

  12. Gelman M, Chakeres D, Newton HB: Brain tumors: complications of cerebral angiography accompanied by intra-arterial chemotherapy. Radiology 213: 135-140, 1998

    Google Scholar 

  13. National Cancer Institute: Common Toxicity Criteria. Bethesda, MD, NCI, 1998

    Google Scholar 

  14. Brown MT, Friedman HS, Oakes WJ, Boyko OB, Hockenberger B, Schold SC: Chemotherapy for pilocytic astrocytomas. Cancer 71: 165-172, 1993

    Google Scholar 

  15. Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ: Chemotherapy for advanced CNS ependymoma. J Neuro-Oncol 45: 61-67, 1998

    Google Scholar 

  16. Doolittle ND, Miner ME, Hall WA, Siegal T, Hanson EJ, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637-647, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Newton, H.B., Ann Slivka, M., Stevens, C.L. et al. Intra-arterial Carboplatin and Intravenous Etoposide for the Treatment of Recurrent and Progressive Non-GBM Gliomas. J Neurooncol 56, 79–86 (2002).

Download citation

  • Issue Date:

  • DOI: